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of acute G2 GU toxicity was about 3 times if the prostate 
volume is ≥ 80 cc (p -value 0.004; 95% CI: 1.05 - 9.5). In the 
adjusted prediction model using the logistic regression, the 
probability of acute G2 GU toxicity was about 60% with the 
same prostate volume cut-off (p-value 0.001; 95% CI: 0.13 - 
0.46), with an attitude to develop a moderate toxicity in the 
first 3 weeks from the beginning of treatment. In the late 
setting, a trend to significance (p=0.076) to develop an acute 
GU toxicity ≥ G1 was found for bladder V60 Gy ≥ 15%. 
 
Conclusion: In moderate hypofractionation in 30 fractions for 
prostate cancer, a prostate gland volume greater than 80 cc 
resulted as predictor of moderate acute GU toxicity. 
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Purpose or Objective: We have created and implemented in 
our department a new scheme of hypofractionated salvage 
volume modulated arc therapy with simultaneous integrated 
boost for patients with recurrence of prostate cancer (PCa) 
after radical prostatectomy (RP). The aims of our research 
are to evaluate toxicities and biochemical response rate. 
 
Material and Methods: Patients with recurrence of PCa after 
RP have been treated by hypofractionated (HF) salvage 
radiotherapy (SRT). Сharacteristics of HF radiotherapy were 
as follows: the prescribed dose to the regional lymphatic 
nodes was 46.8 Gy of 1.8 Gy per fraction, to the prostate bed 
- 61.1 Gy of 2.35 Gy per fraction in case of biochemical 
recurrence (BR) and if region of clinical recurrence (CR) was 
identified - 65 Gy of 2.5 Gy each, in 26 fractions with 
pretreatment imaging; VMAT (two arcs: CW (185°-175°), CCW 
(175°-185°) technology with SIB was used. Toxicities were 
scored using RTOG/EORTC Radiation Toxicity Grading. 
 
Results: 41 patients were treated by the HF SRT. Median 
follow-up was 22 months (10 - 30). Biochemical control rate – 
37 (90.2%) patients, locoregional control rate – 41 (100 %) 
patients. No grade 3 or greater acute toxicities were 
observed.  
 
Conclusion: We would like to suggest a new scheme of HF 
SRT with SIB in 26 fractions for patients with recurrence of 
PCa after RP. The toxicities and early biochemical response 
rates were comparable with conventional fractionation SRT.  
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Purpose or Objective: The Aim of this study is to evaluate 
PSA kinetics in men with intermediate and high risk prostate 
cancer treated with HDR brachytherapy boost in combination 
with external beam radiotherapy (EBRT) and short term 
androgen deprivation therapy (ADT). 
 
Material and Methods: Data from 134 consecutive patients 
treated with HDR brachytherapy boost in combination with 
external beam radiotherapy was extracted from a 
prospectively maintained database. All the patients had a 
minimum follow up of 4 years. Patients who were on 
androgen deprivation therapy for over 12 months were 
excluded from the analysis. After exclusion we had 95 
evaluable patients. All patients received either 17 Gy in 2 
fractions or 15 Gy in single fraction of HDR brachytherapy 
boost followed by external beam radiotherapy 37.5 Gy in 15 
fractions. 70% of patients received Androgen deprivation 
therapy (ADT) for less than or equal to 6 months, 15% 
received for 6- 12 months, and 15% received no hormones. 3-
6 months of ADT was given neoadjuvantly. Date of HDR boost 
was considered as time=0. Benign PSA bounce was defined as 
PSA rise of >0.2ng/ml followed by subsequent decline to pre 
bounce level. 
 
Results: Median follow-up was 4.3 years. At the time of 
median follow up the median PSA was 0.19. PSA bounce was 
seen in 32.6% (n=31). Magnitude of PSA bounce was <1ng/ml 
in 55% (n=17), 1-2ng/ml in 13% (n=4), >2ng/ml in 32% (N=10). 
In 16 out of 17 patients with a PSA bounce of <1ng/ml was 
due to a benign bounce. 50% of patients with a PSA bounce 
between 1-2ng/ml had a benign bounce and the remaining 
50% developed biochemical failure. In 9 out of 10 patients 
who had a PSA bounce of >2ng/ml subsequently developed a 
biochemical failure . Most common  




Conclusion: PSA bounce is a common phenomenon which 
occurs in about a third of men who were treated with short 
term ADT in combination with HDR boost and EBRT. Benign 
PSA bounce tends to have a smaller magnitude of rise in PSA 
<1ng/ml. However patients who developed biochemical 
failure had PSA bounce of larger magnitude >2ng/ml. 
Investigators at the time of submission of the abstract are 
examining variables which predict PSA bounce. 
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Purpose or Objective: A retrospective analysis in 368 
consecutives organ confined prostate cancer (PC) patients 
has been made for evaluating the rates of haematuria, 
etiology and onset time. All these patients have been treated 
from September 2001 to December 2013 with different 
multimodality radical radiotherapy approaches: Intensity 
Guided Modulated radiotherapy (IGRT), Low dose rate 
brachytherapy (LDR BT) exclusively, LDR BT plus External 
radiotherapy (EBRT) or High dose rate Brachytherapy (HDR-
BT) plus EBRT. 
 
Material and Methods: Median age of the whole group was 
70,5 years (range 60-81y). Median PSA at diagnostic of the 
prostate cancer was 9.3 ng/ml (range 4,67-95 ng/ml). Median 
Gleason 6 (range 2-10). 20 patients (41,47%) had received 
IGRT radiotherapy treatment, 4 patients (8%) LDR BT, 10 
patients (21%) LDR plus EBRT and 14 patients (30%) HDR-BT 
plus EBRT. In 17 patients (35,4%) the complete pelvis (L5-S1) 
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was irradiated receiving 50,4 Gy. The comorbidities 
associated were: 21% diabetes, 62,5% High blood pressure, 
40% cardiac pathology and 33 % were with anticoagulant 
treatment. All our haematuria patients have been handled 
following the next algorithm: Blood Test (Including platelets 
and liver parameters) and Urine Culture. If both are negative: 
Ultrasound (Kydney, urether and bladder). If haematuria goes 
on: Cystoscopy. 
 
Results: With a median follow-up of 52.5 months (range 5-
122 m), 48 patients (13%) have had haematuria. As etiological 
factors we have been found: Urine Infection 12 p (25%. Time 
32 months (12-70 m), Bladder cáncer 10 p (21%. Four of them 
a recurrence of a previous treated bladder tumour. Time: 32 
months (3-120 m), RADIATION CYSTITIS 10 p (21%. Time: 13 
months (6 – 38 m), Lithiasis 4 p (8%. Time: 25.5 months (26-
30 m), Local progression of Prostate cancer 1 p (2%). Time: 
72 months), Autolimited haematuria (Culture and image 
studies negatives. It does not repeat.): 9 p (19%. Time: 58 
months (25-80 m) and Fatal haematuria (Exitus. Not known 
etiology): 2 p (4%. Time: 78 and 84 months). 
 
Conclusion: In our experience, haematuria is a frecuent 
pathology in patients treated with radiotherapy of prostate 
cancer. The etiology of it spreading in similar proportions, 
across the different causes founded. The time of it 
presentation is important for the diagnostic. In the mind of 
the specialist must be different causes of it, NOT ONLY 
radiotherapy Cystitis taking in account that if it is due to 
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Purpose or Objective: Volumetric modulated arc therapy 
(VMAT), a complex treatment strategy for intensity-
modulated radiation therapy, has been established clinically. 
While 5 mm thick MLC (L50) is a usual for VMAT, we have 
been using 2.5 mm thick MLC (L25) from 2012 to treat the 
prostate cancer. So we compared dosimetric, volumetric and 
dose delivering parameters between L25 and L50. 
 
Material and Methods: Twenty four cases were selected from 
our database. Those patients were treated for the prostate 
carcinoma in the feet-first prone position. Gantry angle range 
was 182 deg. to 178 deg. and collimation angle was set 0 deg. 
SmartArc system of Pinnacle3 was used with 6MVX physical 
data of Novalis Tx (L25) and 6MVX Siemens® ARTISTE 
physical data loaded on Varian Clinac-21 Ex (the base 
machine of Novalis) virtually (L50). The same consolidations 
for optimization were used. For example, Min Dose, D95 and 
Max Dose of PTV were 76 Gy, 80 Gy and 84 Gy, respectively. 
Rectal V40 was set to 20%. Wilcoxon rank sum test was 
applied to D98, D95, D50 and D02 of PTV, rectal V40, 
irradiation time and MU. To analyze relationships between 
these values and ROV grouped by L25 or L50, linear 
regression model was employed with analysis of covariance 
for the regression coefficients.  
 
Results: Mean values of D98, D95, D50 and D02, V40, Time 
and MU were 75.8 Gy, 77.5 Gy, 81.2 Gy, 84.2 Gy, 20.3%, 82.7 
sec and 646.6 for L25, and were 75.6 Gy, 77.3 Gy, 81.0 Gy, 
83.8 Gy, 19.6 %, 149.9 sec and 741.6 for L50, respectively. 
Only those mean values of D02, V40 and Time were 




D98, D95, V40, Time and MU depended on ROV significantly. 
Slopes of valuables grouped by L25 and L50 were very similar 




Conclusion: L25 and L50 plans were very similar from the 
dosimetric point of view (difference of D02 was significant 
but very small in value; 0.4Gy, L25>L50). From the 
volumetric (V40) point of view, difference was small (0.7%, 
L25>L50) but significant. In terms of dose delivery (Time), 
differences were remarkable and largely depend on the ROV 
especially in the cases of L50. We may use L50 with the 
expense of treatment time compared to L25. 
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Purpose or Objective: For patients with clinically localized 
prostate cancer with high probabilities to undergo adjuvant 
radiotherapy after radical prostatectomy(RP), radical 
radiotherapy may be a proper treatment option for saving 
time and medical costs. Our purpose is to develop 
nomograms combining PSA level, clinical T stage, and biopsy 
Gleason Score to predict probabilities of having indications 
for adjuvant radiotherapy including extraprostatic extension, 
positive margin, Gleason Score 8-10 and to provide data for 
individualizing initial treatment options. 
 
Material and Methods: We analyzed 214 men treated with RP 
between August 2013 and August 2015 at our hospital. 
Average age was 66 years. Men who enrolled in this study had 
a preoperative PSA level assessed before or at least 4 weeks 
after prostate biopsy, biopsy Gleason Score, pelvic MRI and 
clinical T stage (TNM 2009 classification). Men were excluded 
for preoperative treatment with neoadjuvant hormonal 
therapy, or transurethral resection of the prostate because of 
potential influence on pathologic stage or PSA level. 
Preoperative predictors included PSA level, clinical T stage 
(T2a/b, T2c, T3a, T3b), and biopsy Gleason score (5-6, 
3+4=7, 4+3=7, 8-10). These predictors were used in 
multivariable logistic regression analysis based nomograms to 
estimate the probabilities of extraprostatic extension, 
positive margin, Gleason Score 8-10 after RP, respectively. 
The predictive accuracy and discriminative ability of the 
